News
Latest news
— 27 June 2022
Isabelle Eimer to become President of Biogroup
The Biogroup group announces that Dr Isabelle Eimer, MD PhD, president of CAB SELAS, one of the group’s main SELAS, will take over the presidency and management of the Biogroup group. She succeeds Stéphane Eimer, who died suddenly on 22 June 2022.
Isabelle Eimer joined the group in 2005 and over the years has chaired several companies in the group founded and managed by Stéphane Eimer, and has been closely involved in all strategic decisions. With her extensive knowledge of the group, Isabelle Eimer intends to continue the development and activity of the family-owned Biogroup in the entrepreneurial spirit that has always driven the group of talents that Stéphane Eimer brought together.
Biogroup is managed by a solid and experienced team that has accompanied the company for several years. The Group will ensure that the governance evolves so that it can continue its development as the European leader in medical biology.
“Biogroup is a strong company with an ambitious development and an outstanding performance. I wish to preserve our strong entrepreneurial and family culture which has made Biogroup a fast-growing company, established in France and in Europe, and rich in its team of biologists for the greater benefit of patients and health”, declared Isabelle Eimer, President of Biogroup.
— 27 June 2022
Isabelle Eimer prend la présidence de Biogroup
Le groupe Biogroup annonce que Mme Isabelle Eimer, biologiste de formation et présidente de la SELAS CAB, une des principales SELAS du groupe, va assurer la présidence et la direction du groupe Biogroup. Elle succède ainsi à Stéphane Eimer, décédé brutalement le 22 juin 2022.
Entrée dans le groupe en 2005, Isabelle Eimer a présidé, au fil des années, plusieurs sociétés du groupe fondé et dirigé par Stéphane Eimer, et a été étroitement associée à l’ensemble des décisions stratégiques. Forte de sa parfaite connaissance du groupe, Isabelle Eimer entend poursuivre le développement et l’activité du groupe familial Biogroup dans l’esprit entrepreneurial qui a toujours animé le collectif de talents qu’avait réuni Stéphane Eimer.
Biogroup s’appuiera sur une équipe expérimentée et solide qui l’a accompagné depuis plusieurs années et s’assurera de faire évoluer la direction du groupe afin que celle-ci puisse poursuivre son développement comme leader européen de la biologie médicale.
« Biogroup est une société solide qui connaît un développement ambitieux et une performance exceptionnelle. Je souhaite préserver notre culture entrepreneuriale et familiale forte qui fait de Biogroup une entreprise en forte progression, implantée en France comme en Europe et riche de son collectif de biologistes pour le plus grand bénéfice des patients et de la santé », a déclaré Isabelle Eimer, Présidente de Biogroup.
— 23 June 2022
All of the Managers and employees of Biogroup are very sad to inform you of the death of our founding manager, Dr Stéphane Eimer.
Stéphane Eimer has built a strong group in France and in Europe. All of the group’s managers and employees will carry on his achievements with dedication.
We extend our deepest condolences to Stephane’s family and loved ones.
— 01 July 2021
Appointment of Remy Fassin succeeding Severine Bersauter.
— 9 February 2021
Biogroup has successfully completed a refinancing of its existing debt. The refinancing comprises a term loan B borrowed under a new senior facilities agreement, the issuance of €800 million in aggregate principal amount of 3.375% senior secured notes due 2028 and the issuance of €250 million in aggregate principal amount of 5.000% senior notes due 2029.
The new senior facilities agreement consists of a term loan B in an aggregate principal amount of €1,450 million with a seven-year maturity and a revolving credit facility providing for borrowings up to a principal amount of up to €271 million with a 6.5 year maturity.
The transaction represents the initial issuance of high yield notes by Biogroup.